Results 131 to 140 of about 1,211,683 (168)

Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act [PDF]

With substantial fixed costs of drug development, more common conditions can support more products. If additional pharmaceutical products are beneficial, they will attract greater consumption and promote better health, e.g. greater longevity.
Frank R. Lichtenberg, Joel Waldfogel
core  

Ten‐Year Medicare Use and Spending on the 10 Drugs Selected for Negotiation Under the Inflation Reduction Act

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Mohammed Essa, Joseph S. Ross, Sanket S. Dhruva, Nihar R. Desai, Erica S. Spatz, Kamil F. Faridi   +5 more
doaj   +1 more source

Assessing the feasibility and likelihood of policy options to lower specialty drug costs. [PDF]

Health Aff Sch
Taylor EA, Khodyakov D, Predmore Z, Buttorff C, Kim A.   +4 more
europepmc   +1 more source

Outpatient chemotherapy drug costs and expensive chemotherapy drug use in 340B and Non-340B hospitals: an observational study. [PDF]

BMC Health Serv Res
Hu J, Nerenz DR.
europepmc   +1 more source

Health Care Savings from Personalizing Medicine Using Genetic Testing: The Case of Warfarin [PDF]

Progress towards realizing a vision of personalized medicine - drugs and drug doses that are safer and more effective because they are chosen based on an individual's genetic makeup - has been slower than once forecast.
Lutter, Randall, McWilliam, Andrew, Nardinelli, Clark   +2 more
core   +1 more source

Benefits and Costs of Newer Drugs: An Update [PDF]

We update and extend our previous study of the effect of drug age -- years since FDA approval -- on total medical expenditure, in several respects. The estimates indicate that, in the entire population, a reduction in the age of drugs utilized reduces ...
Frank Lichtenberg
core  

Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs. [PDF]

PLoS One, 2019
Murimi-Worstell IB, Ballreich JM, Seamans MJ, Alexander GC.   +3 more
europepmc   +1 more source

Patterns of borrowing to finance out-of-pocket prescription drug costs in Canada: a descriptive analysis. [PDF]

CMAJ Open, 2018
Kolhatkar A, Cheng L, Morgan SG, Goldsmith LJ, Dhalla IA, Holbrook AM, Law MR.   +6 more
europepmc   +1 more source

The misrepresentation of high drug costs: Who is looking out for the patient? [PDF]

Can Pharm J (Ott), 2017
Bachynsky JA, Tsuyuki RT.
europepmc   +1 more source